Search KLH Site
Find Articles by Tags
Addiction (18) Adjuvant - Alum (1) Adjuvant - GPI-0100 (1) Adjuvant - IL-4 (9) Adjuvant GM-CSF (16) Adjuvant KLH (4) Adjuvant Oil / Surfactant (4) Adjuvant QS-21 (25) Age & Physical Activity (3) Allergen-specific immunotherapy (1) Allergy – Pollen (2) Alzheimer's Disease (3) Antibody Response (35) Antibody Response IgA (14) Antibody Response IgE (6) Antibody Response IgG (106) Antibody Response IgM (71) Antibody Response IgY (1) APEC (1) Assay - Bioassay (2) Assay - Carbohydrate Microarray (1) Assay - ELISA (55) Assay - ELISPOT (7) Assay - Immunoassay (8) Assay - InVitro (18) Assay - InVivo (1) Atopic Dermatitis (1) Autoimmune Disease (1) B-epitope (1) Bone Marrow Transplant (6) Cancer (6) Cancer - Bladder (16) Cancer - Brain & CNS (8) Cancer - Breast (15) Cancer - Cervical (1) Cancer - Colorectal (10) Cancer - Esophageal (1) Cancer - Female Reproductive (7) Cancer - Leukemia (2) Cancer - Lung (4) Cancer - Lymphoma (25) Cancer - Melanoma (37) Cancer - Mesothelioma (1) Cancer - Myeloma (15) Cancer - Other (2) Cancer - Ovarian (3) Cancer - Pancreas (1) Cancer - Pediatric (3) Cancer - Peritoneal (2) Cancer - Prostate (9) Cancer - Renal (13) Cancer - Sarcoma (2) Clostridium difficile (5) Crohn's Disease (2) Cross-Reactive Antigens (6) Delayed-type hypersensitivity response (1) Dendritic Cell (66) Developmental (10) Diabetes (2) Disease Resistence (1) DNP-Ficoll (2) DTH (67) Environmental (15) Escherichia coli (1) Fingolimod (Gilenya) (1) Healthy Volunteers (18) HealthyAntibody Response - IgA (1) Hepatitis (2) HIV (11) HPV (3) Husbandry (3) Hypertension (1) id-KLH (29) IL 1 (4) IL 12 (2) IL 15 (1) IL 2 (10) IL 5 (1) IL 6 (1) IL 7 (1) Immune Disease - Autoimmune (13) Immune Disease - Primary (2) Immune Disease – Secondary (1) Immune Response - Cellular (187) Immune Response - Humoral (259) Immune Response Humoral (2) Immunotoxicity (37) Infection (1) Infectious Disease (5) Inflammatory Disease (1) Intradermal KLH (1) Kidney (1) KLH-BEC2 (1) KLH-BP16 (1) KLH-BPO (1) KLH-Conjugate (69) KLH-EGFR (2) KLH-FITC (1) KLH-Ganglioside (16) KLH-Globo H (7) KLH-GM2 (1) KLH-hD1 (1) KLH-HGP-30 (1) KLH-IL (1) KLH-Kinoid (8) KLH-Lewis Y (3) KLH-MUC (8) KLH-Oxycodone (2) KLH-sTn (9) KLH-TF (5) KLH-TN (3) Model - Canine (6) Model - Guinea Pig (10) Model - Livestock (10) Model - Mouse (73) Model - Other (32) Model - Primate (12) Model - Rat (51) Multiple Sclerosis (1) Nasal (3) Natrural Antibody (1) Neonatal (2) NK Cells (1) NSAID (1) Oral KLH (9) Oxycodone (3) Parasitic Disease (6) Pediatric (1) Plant-made (2) PLNA (1) Population Density (3) Psoriasis (1) Review Article (2) Rheumatoid Arthritis (11) Rituximab (Rituxan) (4) Russian thistle (1) Sal k 1 (1) Stress (8) Systemic Lupus Erythematosus (SLE) (7) TACA (2) TDAR (127) Therapeutics - KLH Alone (15) Transplant (6) Ultra Violet radiation (1) Uveitis (1) VEGF (3) Veterinary (1)
Terms and Privacy

KLH in Publications

Publications of scientific research involving KLH. Abstracts or full text articles are available by link to outside sites. If you know of a KLH-related publication that is not yet on KLH Site™, let us know.

(in order by date)

Entries in id-KLH (29)


Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients

Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR

Bone Marrow Transplant. 2013 Feb;48(2):269-77. doi: 10.1038/bmt.2012.132. Epub 2012 Jul 9


Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.

Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR

Bone Marrow Transplant. 2012 Jul 9. doi: 10.1038/bmt.2012.132. [Epub ahead of print]


Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED.

Biol Blood Marrow Transplant. 2012 Feb;18(2):257-64. Epub 2011 Jul 4


Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.

Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S

J Immunother. 2011 Jan;34(1):100-6


Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.

J Clin Oncol. 2009 Jun 20;27(18):3036-43. Epub 2009 May 4.


Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells

David J. Betting, Xi Y. Mu, Kamran Kafi, Desmond McDonnel, Francisco Rosas, Daniel P. Gold, and John M. Timmerman. 

Vaccine. 2009 January 7; 27(2): 250–259


Prolonged idiotypic vaccination against follicular lymphoma

Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M.

Leuk Lymphoma. 2009 Jan;50(1):47-53


Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma

John M. Timmerman, Julie M. Vose, Debra K. Czerwinski, Wen-Kai Weng, Diane Ingolia, Martha Mayo, Dan W. Denney, and Ronald Levy.  

Leuk Lymphoma. 2009 January; 50(1): 37–46.


Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines

Kamran Kafi, David J. Betting, Reiko E. Yamada, Michael Bacica, Kristopher K. Steward, and John M. Timmerman. 

Mol Immunol. 2009 January; 46(3): 448–456


Developing idiotype vaccines for lymphoma: From preclinical studies to Phase III clinical trials

Hyun Jun Park and Sattva S. Neelapu, M.D.  

Br J Haematol. 2008 June; 142(2): 179–191


Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.

Koumarianou A, Kountourakis P, Economopoulos T.

J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):230-2. Epub 2008 Mar 7.


Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo

Suzanne N. Franki, Kristopher K. Steward, David J. Betting, Kamran Kafi, Reiko E. Yamada, and John M. Timmerman.

Blood. 2008 February 1; 111(3): 1504–1511.


Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.

Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.

Br J Haematol. 2007 Nov;139(3):415-24.

Full Text


BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.

Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS.

Expert Opin Biol Ther. 2007 Jan;7(1):113-22.


Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.

Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF.

J Clin Oncol. 2006 Jul 1;24(19):3107-12. Epub 2006 Jun 5.

Full text


Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.

Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N,Giraldo P, San Miguel J, Orfao A.

Leuk Lymphoma. 2006 Jan;47(1):29-37.


Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.


Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.

Curti A, Isidori A, Ferri E, Terragna C, Neyroz P, Cellini C, Ratta M, Baccarani M, Lemoli RM.

Leuk Lymphoma. 2004 Jul;45(7):1419-28.


Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.  

Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.

Leukemia. 2004 Jan;18(1):139-45.


Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.

Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P.

Haematologica. 2003 Oct;88(10):1139-49.